

Statement regarding the use of opioid analgesics in patients with chronic non-cancer pain

FOREGROUND PAPER

Preamble

- A. The Faculty of Pain Medicine (FPM) recognises the lack of definitive evidence supporting the long-term effectiveness of opioid analgesics in people experiencing chronic non-cancer pain (CNCP) and the substantial evidence for potential harm.
- B. The FPM recognises that opioids are widely and often inappropriately prescribed for CNCP despite the lack of clear evidence of efficacy.
- C. The FPM also recognises the changed regulatory environment introduced in Australia by the TGA¹ in 2020, specifically²:
- “[Modified-release opioid product] is indicated for the management of severe pain where
- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
 - the pain is opioid-responsive, and
 - requires daily, continuous, long term treatment.
- “[Modified-release opioid product] is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.”
- D. The FPM interprets “exceptional circumstances” in this context to denote:
- Severe pain,
 - for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management, *and*
 - which has been shown to be opioid-responsive
- E. In New Zealand, Medsafe has not taken an overarching regulatory approach. The indications for each drug are listed in its data sheet.³ Some but not all products mention criteria such as opioid-responsiveness, failure of conservative methods of analgesia, and absence of psychological contraindication, drug-seeking behaviour or history of drug misuse. CNCP is not necessarily specified.
- F. This document describes the current position of the FPM regarding the prescription of opioids in CNCP, presented as a series of principles. The accompanying Background Paper provides detail regarding the evidence and reasoning underpinning these principles.

¹ Therapeutic Goods Administration, Department of Health, Commonwealth of Australia

² Therapeutics Good Administration. Prescription opioids hub: Upcoming changes to reduce harm. <https://www.tga.gov.au/node/877210>: TGA, 2020. Accessed 11/3/2020.

³ [https://www.medsafe.govt.nz/Profs/Datasheet/\[product\]](https://www.medsafe.govt.nz/Profs/Datasheet/[product]) Accessed 31/3/2020.

PRINCIPLES

1. GENERAL PRINCIPLES INFORMING THE MANAGEMENT OF PATIENTS WITH CHRONIC NON-CANCER PAIN

- 1.1 Careful assessment of the social, psychological and biomedical contributors⁴ to the person's presentation should be undertaken to inform a management plan for people with CNCP.
- 1.2 The first line of therapy for CNCP involves engaging the person to develop pain self-management skills⁵.
- 1.3 Second line therapies in CNCP include drug treatment which, while not a core component of a management plan, may play a role in facilitating functional goals and maintaining social roles including employment.
- 1.4 Drug treatment for the patient with CNCP is only ever part of a multimodal plan towards self-management and should be prescribed on a time-limited basis.
- 1.5 Drug treatment with opioids in patients with CNCP may be considered in the exceptional circumstances described in Preamble point D above.

2. PRINCIPLES INFORMING THE PRESCRIPTION OF OPIOIDS TO PATIENTS WITH CHRONIC NON-CANCER PAIN

2.1 General

- 2.1.1 Opioid treatment in CNCP is always an ongoing individual trial of therapy. Prescription of opioids, in the context of Principle 1.5 above, is contingent upon:
 - demonstration of benefit;
 - active surveillance for harms; and
 - periodic attempts at dose minimisation.
- 2.1.2 It is the responsibility of each prescriber to be thoroughly acquainted with:
 - the clinical pharmacology of the opioid(s) to be prescribed;
 - the efficacy and harms of those opioids;
 - the interactions of opioids with other drugs; and
 - the regulatory requirements imposed by the jurisdiction in which they practise.
- 2.1.3 The aim of an opioid analgesic trial is to discover the individual's responsiveness to this therapy in terms of improved quality of life. This requires clear articulation of the goals of the trial, including an agreement that if the goals are not met, then this treatment will be withdrawn.⁶

Such goals extend beyond pain relief alone, to include improvement in activity and participation.⁷ Goals need to be negotiated according to the individual's wishes and capability.
- 2.1.4 Opioid treatment requires regular, documented assessment that addresses the "5As":
 - analgesia
 - activity
 - adverse effects
 - affect
 - aberrant behaviour

⁴ Sociopsychobiomedical Assessment. Faculty of Pain Medicine, ANZCA, Curriculum 2015-. <http://fpm.anzca.edu.au/training/2015-training-program>. 2015.

⁵ Pain self-management skills development is a process where a person learns ways to manage their symptoms and achieve goals (Nicholas & Blyth. Pain Management, 2016;6(1):75-88).

⁶ This could be incorporated into an "opioid contract".

⁷ The International Classification of Functioning Disability and Health model (ICF) describes body functions, activities and participation.

- 2.1.5 The criteria for “opioid-responsiveness” may include but are not limited to:
- increase in function, as determined by an agreed activity or set of activities, assisted by instruments such as BPI⁸ or PEG⁹
 - absence of limiting side-effects, especially those that might interfere with sleep, learning and active self-management
 - reduction in pain, quantified by instruments such as BPI, PEG, VAS¹⁰, NRS¹¹
 - sustained response over time, not requiring dose escalation
- 2.1.6 If goals are met during a trial, then it is important to determine the lowest dose of opioid that is associated with sustained benefit. This dose may not be zero.
- 2.1.7 If the opioid trial goals are not met, then a process of weaning should be commenced. Specific weaning strategies in the context of transition to self-management include:
- 2.1.7.1 In situations where opioid therapy has been maintained for a long time without meaningful improvement in function, the desired outcome is weaning to cessation if possible. One practical strategy is to reduce the daily opioid dose each month by 10-25%.
- 2.1.7.2 If weaning is required after a shorter period of opioid therapy, such as after failure to achieve the goals of an opioid trial, or after a negotiated treatment phase for acute pain, then a faster rate of weaning is generally appropriate. One option is a step-wise reduction of the daily opioid dose each week by 10-25%.
- 2.1.7.3 If weaning is required in response to significant adverse effects or opioid misuse, then daily step-wise reduction may be more appropriate. Alternatively, immediate opioid cessation and pharmacological treatment of withdrawal symptoms can be considered.
- 2.1.7.4 If an attempt at opioid weaning has proven unsuccessful, then the rate can be slowed. This can be achieved by reducing the size of the dose reduction and/or by increasing the time spent at each dose level (e.g. 2 or 3 months between reductions).
- 2.1.7.5 In cases where it becomes apparent during weaning that the primary problem is opioid dependence rather than pain, involvement of an Addiction Medicine service is recommended.
- 2.1.7.6 Use of complex pharmacological treatments to assist weaning should be undertaken only by practitioners accredited in such treatment modalities.
- 2.1.8 During the period of opioid weaning,
- ongoing attempts to develop pain self-management skills remain important
 - compliance with regulatory requirements remains essential
 - limited dispensing and urine drug screening may be considered.
- 2.2 Additional principles underpinning management of the patient already established on opioids (the “inherited” or “legacy” patient)**
- 2.2.1 Reassessment of the social, psychological and biomedical contributors to the person’s presentation should be performed and repeated over time.
- 2.2.2 Consolidation of all opioid formulations to one opioid formulation should be undertaken, guided by contemporary equianalgesic tables.¹²

⁸ BPI: Brief Pain Inventory (Tai G, Jensen MP, Thornberg JI, Shouti BF. Validation of the Brief Pain Inventory for chronic non-malignant pain. J Pain 2004(2); 5:133-137.)

⁹ PEG Pain-Enjoyment-General Activity scale of pain intensity and interference (Krebs EE, Lorenz KA, Bair MJ, et al. Development and Initial Validation of the PEG, a Three-item scale Assessing Pain Intensity and Interference. J Gen Intern Med 2009; 24(6): 733- 738.)

¹⁰ VAS: visual analogue (pain) scale

¹¹ NRS: numerical rating (pain) scale

¹²As per FPM Opioid Calculator app v 2.7.1 and document [www.fpm.anzca.edu.au/documents/opioid-dose-equivalence.pdf]

2.3 Additional principles underpinning initiating a trial in an opioid-naïve patient

- 2.3.1 A trial of opioid drug treatment may be considered after comprehensive assessment and trials of non-drug therapy and non-opioid drug treatment, as part of a multimodal plan facilitating self-management, according to principles 1.5 and 2.1.1 above.
- 2.3.2 Although short-acting opioids may be useful in determining initial opioid-responsiveness in CNCP, as in 2.1.5 above, they should not be prescribed over the longer term, out of consideration for the development of tolerance and the potential for positive reinforcement of drug-taking behaviour. A definitive trial should be determined using long-acting or modified-release opioid preparations.
- 2.3.3 Transdermal fentanyl should not be initiated in CNCP.
- 2.3.4 Ascertainment of opioid-responsiveness by titration of dose should be achievable within two months of initiation.
- 2.3.5 Opioid-responsiveness should be evident at oral morphine equivalent (OME) doses $\leq 60\text{mg}$ per day.^{13,14} If doses exceed this, specialist consultation should be sought.

2.4 Response to difficulty achieving or maintaining therapeutic goals in an opioid trial

- 2.4.1 Difficulty in establishing opioid-responsiveness in the context of the individually tailored goals of an opioid trial, as defined above, may be attributable to pharmacodynamic, pharmacokinetic or behavioural factors.
- Pharmacodynamic factors, such as non-responsiveness of distress or development of intolerable adverse effects, and pharmacokinetic factors, such as insufficient (or excessive) duration of effect, may respond to change in opioid preparation or change in dosing regimen.
 - Behavioural factors, such as poor activity pacing, may respond to reinforcement of pain self-management skills.
- 2.4.2 Variations in stability of dose and responsiveness over time, including apparent increase in dose requirements may reflect change in the underlying biomedical contribution, development of tolerance, changes in mood, social circumstances or other stressors, or development of aberrant drug-taking behaviour. Such situations require comprehensive reassessment.
- 2.4.3 Actions arising out of such reassessment may include:
- recalibration of goals of therapy
 - reconsideration of other modes of therapy
 - consultation with colleague(s)
 - opioid reduction to the minimum effective dose or cessation

¹³ NSW Therapeutic Advisory Group Inc., Preventing and managing problems with opioid prescribing for chronic non-cancer pain. NSW TAG: Sydney, 2015

¹⁴ http://www.aci.health.nsw.gov.au/chronic-pain/health-professionals/quick_steps_through_opioid_management

Faculty of Pain Medicine Professional Documents

POLICY – A document that formally states principle, plan and/or course of action that is prescriptive and mandatory.

STATEMENT – A document that describes where the college stands on a particular issue. This may include areas that lack clarity or where opinions vary. A statement is not prescriptive.

GUIDELINE – A document that offers advice on a particular subject, ideally based on best practice recommendations and information, available evidence and/or expert consensus. A guideline is not prescriptive.

This document has been prepared having regard to general circumstances, and it is the responsibility of the practitioner to have express regard to the particular circumstances of each case, and the application of this policy document in each case.

Professional documents are reviewed from time to time, and it is the responsibility of the practitioner to ensure that the practitioner has obtained the current version. Professional documents have been prepared having regard to the information available at the time of their preparation, and the practitioner should therefore have regard to any information, research or material which may have been published or become available subsequently.

Whilst the College and Faculty endeavours to ensure that documents are as current as possible at the time of their preparation, they take no responsibility for matters arising from changed circumstances or information or material which may have become available subsequently.

Promulgated: August 2010

Reviewed: 2020

Date of current document: April 2020

© Copyright 2020 – Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from ANZCA. Requests and inquiries concerning reproduction and rights should be addressed to the Chief Executive Officer, Australian and New Zealand College of Anaesthetists, 630 St Kilda Road, Melbourne, Victoria 3004, Australia. Email: ceoanzca@anzca.edu.au

ANZCA website: www.anzca.edu.au

FPM website: www.anzca.edu.au/fpm